Loading clinical trials...

Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab | Clinical Trials | Clareo Health

UNKNOWNPHASE1

Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab

NCT05737368•Second Affiliated Hospital, School of Medicine, Zhejiang University

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and effectiveness in the treatment of recurrent glioblastoma with Cadonilimab combined with fractionated radiotherapy.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. . Written and signed informed consent.
•2. . Male or female, age≥ 18 and ≤ 75 years old on day of signing informed consent.
•3. Epitentorial glioblastoma confirmed by pathology; Diagnosis of recurrence through clinical imaging evidence.
•4. The maximum diameter of recurrent tumor is less than 6 cm.
•5. Concurrent radiotherapy and chemotherapy with standard STUP treatment scheme in the past.
•6. The interval from the last radiotherapy is more than 6 months.
•7. KPS (Karnofsky function status score)\>60.

Exclusion Criteria

•1. Prior use of investigational products or devices within 4 weeks prior to the first administration of the study treatment.
•2. Concurrent enrollment into another clinical study, except the study belongs to investigational, non-interventional studies or the follow-up period of interventional studies.
•3. Multiple malignant gliomas.
•4. Subtentorial glioblastoma or Extracranial metastatic lesions.
•5. Active autoimmune diseases.
•6. Known history of primary immunodeficiency virus infection or known history of testing positive for human immunodeficiency virus (HIV).

Key Dates

Start Date

February 28, 2023

Primary Completion Date

February 28, 2024

Completion Date

February 28, 2025

Last Updated

February 21, 2023

Enrollment

ESTIMATED participants

Conditions

Recurrent Glioblastoma

Interventions

fractionated radiotherapy

RADIATION

cadonilimab

DRUG

Contacts

Wei Yu, MD

CONTACT

+8657187783521 11418282@zju.edu.cn

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

RECRUITINGPHASE1

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

NCT06344130

AstrocytomaGlioma+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 21, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM